Compare HLN & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLN | MIST |
|---|---|---|
| Founded | 2022 | 2003 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7B | 176.3M |
| IPO Year | N/A | 2019 |
| Metric | HLN | MIST |
|---|---|---|
| Price | $10.09 | $1.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 8.0M | 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | N/A | ★ 51.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.04 | N/A |
| Revenue Next Year | $4.58 | N/A |
| P/E Ratio | $49.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.71 | $0.63 |
| 52 Week High | $11.42 | $3.06 |
| Indicator | HLN | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 37.81 | 50.38 |
| Support Level | $9.48 | $1.62 |
| Resistance Level | $10.31 | $1.79 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 9.68 | 86.54 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).